Generare closes €20M Series A in Paris
Paris-based techbio company Generare has raised a €20 million Series A round led by French venture firms Alven and Daphni, as the startup aims to industrialize the creation of new molecular data for the next wave of AI drug discovery.
Targeting nature’s “missing” chemistry
Generare says its platform is designed to unlock what it describes as 97% of nature’s untapped molecular chemistry—chemical space that remains largely inaccessible to traditional screening and data-collection approaches. By systematically generating novel compounds and the associated experimental readouts, the company intends to expand the datasets available to machine-learning models used in early-stage drug development.
Why data is the bottleneck for AI in biopharma
While AI models have improved rapidly, many drug-discovery teams still struggle with limited, noisy, or biased training data. Generare is positioning itself as a data engine: producing new, high-value molecular information that can be used to train and validate predictive models, potentially improving hit identification and lead optimization.
What the funding supports
The company said the Series A will be used to scale its technology and accelerate the production of novel molecular datasets. The round also signals continued investor interest in techbio companies that combine automation, chemistry, and machine learning to shorten R&D timelines.
With backing from Alven and Daphni, Generare joins a growing cohort of European startups betting that proprietary data generation—not just algorithms—will define competitive advantage in AI drug discovery.
Related
